Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer

被引:12
作者
Bitting, Rhonda L.
Armstrong, Andrew J. [1 ]
机构
[1] Duke Univ, Div Med Oncol, Duke Canc Inst, Durham, NC 27710 USA
关键词
Castration-resistant prostate cancer (CRPC); predictive biomarkers; CIRCULATING TUMOR-CELLS; ANDROGEN-RECEPTOR; CLINICAL-TRIALS; END-POINTS; PROGNOSTIC-SIGNIFICANCE; MESENCHYMAL TRANSITION; SKELETAL COMPLICATIONS; INCREASED SURVIVAL; PERIPHERAL-BLOOD; LUNG-CANCER;
D O I
10.1097/PPO.0b013e31827e0b9c
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the surge in therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess disease response. Predictive biomarkers are factors related to the disease or the host that are associated with improvements in outcomes, such as survival, due to specific therapies. Such biomarkers have become of paramount importance in oncology to maximize the benefits of novel systemic agents while minimizing harm to individual patients and the costs to society. Given the number of newly approved and expensive systemic therapies, including novel hormonal therapies, chemotherapies, immunotherapies, and bone microenvironment-targeting therapies, predictive biomarkers are needed to give physicians a more rational sense of matching the right patient to the right therapy sequence at a given time. There are currently no validated predictive biomarkers in CRPC. We discuss potential predictive biomarkers in men with CRPC and how these may be developed in the context of therapeutic clinical trials.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 111 条
[1]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[2]  
[Anonymous], J CLIN ONCOL
[3]  
[Anonymous], ISRN ONCOL, DOI DOI 10.5402/2012/382010
[4]   A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis [J].
Armstrong, Andrew J. ;
Garrett-Mayer, Elizabeth S. ;
Yang, Yi-Chun Ou ;
de Wit, Ronald ;
Tannock, Ian F. ;
Eisenberger, Mario .
CLINICAL CANCER RESEARCH, 2007, 13 (21) :6396-6403
[5]   Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer [J].
Armstrong, Andrew J. ;
Garrett-Mayer, Elizabeth ;
Yang, Yi-Chun Ou ;
Carducci, Michael A. ;
Tannock, Ian ;
de Wit, Ronald ;
Eisenberger, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3965-3970
[6]   Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin [J].
Armstrong, Andrew J. ;
George, Daniel J. ;
Halabi, Susan .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3402-3407
[7]   Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer [J].
Armstrong, Andrew J. ;
Eisenberger, Mario A. ;
Halabi, Susan ;
Oudard, Stephane ;
Nanus, David M. ;
Petrylak, Daniel P. ;
Sartor, A. Oliver ;
Scher, Howard I. .
EUROPEAN UROLOGY, 2012, 61 (03) :549-559
[8]   Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers [J].
Armstrong, Andrew J. ;
Marengo, Matthew S. ;
Oltean, Sebastian ;
Kemeny, Gabor ;
Bitting, Rhonda L. ;
Turnbull, James D. ;
Herold, Christina I. ;
Marcom, Paul K. ;
George, Daniel J. ;
Garcia-Blanco, Mariano A. .
MOLECULAR CANCER RESEARCH, 2011, 9 (08) :997-1007
[9]   Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature [J].
Armstrong, Andrew J. ;
Febbo, Phillip G. .
ONCOLOGIST, 2009, 14 (08) :816-827
[10]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95